FDA Inspection 1201601 — Fresenius Kabi Compounding, LLC

Fresenius Kabi Compounding, LLC — FEI 3013438665

The FDA completed an inspection of Fresenius Kabi Compounding, LLC on March 6, 2023 in Canton, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 6, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Canton, MA (United States)

Citations

IDCFRDescription
145121 CFR 211.113(b)Procedures for sterile drug products
189021 CFR 211.165(e)Test methods